NASDAQ: ABIO - ARCA biopharma, Inc.

Yield per half year: -36.84%
Dividend yield: +66.25%
Sector: Healthcare

Share chart ARCA biopharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About ARCA biopharma, Inc.

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.

more details
ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1997-08-08
ISIN US00211Y5069
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 4.9E-5
Дивиденд ао 0.1285
Сайт https://www.arcabio.com
Цена ао 3.79
Change price per day: 0% (2.4)
Change price per week: 0% (2.4)
Change price per month: 0% (2.4)
Change price per 3 month: 0% (2.4)
Change price per half year: -36.84% (3.8)
Change price per year: +40.35% (1.71)
Change price per 3 year: +1.27% (2.37)
Change price per 5 year: -53.03% (5.11)
Change price per 10 year: 0% (2.4)
Change price per year to date: 0% (2.4)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.6659 10
P/E 0 0
EV/EBITDA 1.71 10
Total: 5

Efficiency

Title Value Grade
ROA, % -14.1 0
ROE, % -14.42 0
Total: 0

Dividends

Title Value Grade
Div yield, % 66.25 10
DSI 1 10
Total: 7.35

Debt

Title Value Grade
Debt/EBITDA -0.0384 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 7721.03 10
Yield Ebitda, % 30.29 5
Yield EPS, % -91.08 0
Total: 3.2
More

Dividend, % Dividend Result of period Buy before Register closing date Payment before
504.1% 19.08 II кв. 2024 27.08.2024 29.08.2024 13.09.2024
More

Institutions Volume Share, %
Cable Car Capital LLC 4000452 27.59
Western Standard, LLC 1410143 9.72
Bml Capital Management, LLC 706930 4.87
Vanguard Group Inc 453598 3.13
Newtyn Management, LLC 269320 1.86
Blackrock Inc. 231911 1.6
Geode Capital Management, LLC 142349 0.98
State Street Corporation 71137 0.49
Renaissance Technologies, LLC 57299 0.4
Dimensional Fund Advisors LP 42514 0.29



Head Job title Payment Year of birth
Mr. Thomas A. Keuer President, COO & Principal Executive Officer 400.8k 1959 (66 years)
Mr. C. Jeffrey Dekker CPA CFO, Treasurer & Company Secretary 323.07k 1965 (60 years)

Address: United States, Westminster. CO, 10170 Church Ranch Way - open in Google maps, open in Yandex maps
Website: https://www.arcabio.com